Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...